1st and 3rd University Departments of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Ophthalmology III, Quinze-Vingts Hospital, Paris, France;Quinze-Vingts Hospital, Paris, France; Inserm, ; RUPMC Univ Paris 06, Institut De La Vision; CNRS, ; CHNO Des Quinze-Vingts, INSERM-DHOS Paris, France; Department of Ophthalmology, Ambroise Paré Hospital, AP-HP, University of Versailles Saint-Quentin-en-Yvelines, Versailles, France.
Expert Opin Drug Saf. 2021 Apr;20(4):453-466. doi: 10.1080/14740338.2021.1873947. Epub 2021 Jan 21.
: Preservative-free (PF) medications represent a valuable treatment strategy in the lifelong management of glaucoma. By removing preservative toxicity, PF formulations provide tangible clinical benefits to glaucoma patients worldwide. They improve tolerability and adherence, leading to a positive impact in long-term intraocular pressure (IOP) control.: A critical review of the subject is provided, including selected evidence on the safety and tolerability of currently available topical PF formulations. Cumulative evidence confirms that topical PF medications are at least equally efficacious to their preserved equivalents. There is convincing short-term evidence for superior tolerability and safety of PF formulations compared to preserved medications. The long-term benefits and success of PF therapy requires further elucidation.: Successful stepwise administration of medical therapy for glaucoma remains elusive. There is a greater risk for ocular toxicity and therapy failure with preserved topical glaucoma therapy. Currently available and emerging PF therapy options potentially optimize lifelong stepwise glaucoma therapy and may enhance outcome. To avert complications from preservatives leading to poor adherence, ideally, future antiglaucoma therapy should become 100% PF. There are still key aspects of PF therapy that warrant further investigation.
无防腐剂(PF)药物是青光眼终身管理的一种有价值的治疗策略。通过消除防腐剂的毒性,PF 制剂为全球青光眼患者提供了切实的临床益处。它们提高了耐受性和依从性,对长期眼压(IOP)控制产生了积极影响。对这一主题进行了批判性的回顾,包括目前可用的局部 PF 制剂的安全性和耐受性的选择证据。累积的证据证实,局部 PF 药物与防腐剂等效物一样有效。与防腐剂相比,PF 制剂在短期和长期均具有更好的耐受性和安全性。PF 治疗的长期益处和成功需要进一步阐明。青光眼药物治疗的成功逐步实施仍然难以实现。保存的局部青光眼治疗有更大的眼部毒性和治疗失败的风险。目前可用和新兴的 PF 治疗选择可能优化青光眼的终身逐步治疗,并可能改善结果。为了避免防腐剂引起的并发症导致依从性差,理想情况下,未来的抗青光眼治疗应 100%采用 PF。PF 治疗仍有一些关键方面需要进一步研究。